Trial Profile
A study evaluating efficacy and tolerability of Panitumumab in patients with metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2017
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology